DJIA 17,387.21 -291.49 -1.65%
NASDAQ 4,681.50 -90.27 -1.89%
S&P 500 2,029.55 -27.54 -1.34%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

70.55 -0.81 (-1.14%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $70.55 -1.14%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $70.56
Previous Close $71.36
Daily Range $70.20 - $71.26
52-Week Range $38.49 - $71.73
Market Cap $10.3B
P/E Ratio -274.46
Dividend (Yield) $0.00 (0.0%)
Volume 804,594
Average Daily Volume 1,317,084
Current FY EPS -$0.14

Sector

Healthcare

Industry

Drugs

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

5 Predictions for Biotechnology Stocks in 2015

Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.

Alkermes plc (ALKS) in Focus: Stock Moves 6.6% Higher - Tale of the Tape

XenoPort Prepping For Key Data In 2015

Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest

The week before JPMorgan Healthcare conference brought a plethora of deals and data.

Alkermes Soars on Positive Schizophrenia Drug Results - Analyst Blog

Great News! An Exciting New Drug for Depression May Be on the Way

In phase 3 trials, Alkermes' ALKS-5461 shows promise for the treatment of depression.

Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog

Biotech Stock Roundup: Kite Flies High on Amgen Deal, Isis Soars on J&J Collaboration - Analyst Blog

See More ALKS News...

ALKS's Top Competitors

ALKS $70.55 (-1.14%)
Current stock: ALKS
AMGN $158.42 (-0.82%)
Current stock: AMGN
GILD $105.03 (-1.94%)
Current stock: GILD
CELG $122.36 (-1.42%)
Current stock: CELG